Lewis Joseph's Form 4/A amendment
AmendedTango Therapeutics, Inc. (TNGX) · filed Oct 17, 2023
- Accession no.
- 0000895345-23-000589
- Filed
- Oct 17, 2023, 7:41 PM ET
- Trade date
- Oct 13-16, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Oct 17, 2023
This filing lists 2 non-derivative transactions. Open-market purchases total $8.72M. It was filed 4 days after the trade.
This amendment replaces 0000895345-23-000588 (filed Oct 17, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lewis JosephCIK 0001015747 | Other: See remarks |
| Boxer Asset Management Inc.CIK 0001465836 | Other: See remarks |
| Boxer Capital, LLCCIK 0001465837 | Other: See remarks |
| Davis Aaron I.CIK 0001465914 | Other: See remarks |
| MVA Investors, LLCCIK 0001468223 | Other: See remarks |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.95 to $7.10, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.54 to $7.01, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
- F4
These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
- F5
These securities are owned directly by Mr. Davis. Each reporting person other than Mr. Davis disclaims beneficial ownership of these securities.
- F6
These securities are owned directly by Braslyn Ltd. Mr. Lewis is the sole indirect own of Braslyn Ltd. Each reporting person other than Mr. Lewis disclaims beneficial ownership of these securities.
- F7
These securities are owned directly by BCTG Holdings, LLC ("BCTG"). Boxer Capital is the majority member of BCTG and MVA Investors is a member of BCTG. Mr. Davis is a member of the investment committee of BCTG. Each reporting person disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
Remarks
The reporting persons may be deemed members of a group that beneficially owns more than 10% of the outstanding shares of common stock, $0.001 par value per share ("Common Stock"), of Tango Therapeutics, Inc. Boxer and Mr. Davis have informed the issuer that the purchases disclosed herein may give rise to profit subject to recovery by the issuer pursuant to Section 16(b) of the Securities Exchange Act of 1934. Without conceding the application of Section 16(b) of the Securities Exchange Act of 1934, Boxer and Mr. Davis have paid to the issuer the entire amount that would be recoverable by the issuer thereunder if the same is applicable to Boxer and Mr. Davis. As to any reporting person that is not a beneficial owner of more than 10% of the outstanding shares of Common Stock, this Form 4 shall not be deemed a concession that such person is subject to Section 16 of the Securities Exchange Act of 1934 with respect to the issuer. This Form 4/A amends and restates the Form 4 filed earlier on the same date.